Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yves Beguin

Showing results (171-180 of 243) with videos related to

Pageof 25
Sort By:
Bulletin Du Cancer|October 7, 2019
[Haploidentical hematopoietic stem cell transplant: How to choose the best donor? Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Valérie Dubois, Kahina Amokrane, Yves Beguin, et al.
Haematologica|May 12, 2018
Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone diseaseJoséphine Muller, Arnold Bolomsky, Sophie Dubois, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG ConditioningMuriel Hannon, Yves Beguin, Grégory Ehx, et al.
Clinical Biochemistry|December 27, 2016
The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian studyFlorence Van Obbergh, Laurent Knoops, Timothy Devos, et al.
Bulletin Du Cancer|September 6, 2025
[Acute graft-versus-host disease therapy: Which third line treatment after steroids and ruxolitinib? (SFGM-TC)]Tereza Coman, Fabio Andreozzi, Jaques-Olivier Bay, et al.
Transplantation and Cellular Therapy|August 24, 2022
Unrelated Cord Blood Transplantation in Children, Adolescents, and Young Adults with Acute Leukemia or Myelodysplastic Syndrome: A Retrospective Comparative Study from the French Society for Bone Marrow Transplantation and Cellular Therapy Between Real-World Data and Previously Reported Results of a Randomized Clinical TrialAnne-Charlotte Teyssier, Gérard Michel, Charlotte Jubert, et al.
Frontiers in Immunology|February 23, 2023
Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: A multicenter prospective analysisSophie Servais, Frédéric Baron, Chantal Lechanteur, et al.
The Oncologist|February 28, 2016
The Changing Landscape of Smoldering Multiple Myeloma: A European PerspectiveJo Caers, Carlos Fernández de Larrea, Xavier Leleu, et al.
Frontiers in Immunology|October 19, 2018
Growth Hormone (GH) Deficient Mice With GHRH Gene Ablation Are Severely Deficient in Vaccine and Immune Responses Against <i>Streptococcus pneumoniae</i>Khalil Farhat, Gwennaëlle Bodart, Chantal Charlet-Renard, et al.
Haematologica|March 20, 2016
Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen for elderly patients (60 years and older) with hematologic malignancies using unrelated donors: a retrospective study from the French society for stem cell transplantation (SFGM-TC)Jean El Cheikh, Patrick Sfumato, Mohamad Sobh, et al.
Pageof 25

Showing results (171-180 of 243) with videos related to

Sort By:
Pageof 25
Bulletin Du Cancer|October 7, 2019
[Haploidentical hematopoietic stem cell transplant: How to choose the best donor? Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Valérie Dubois, Kahina Amokrane, Yves Beguin, et al.
Haematologica|May 12, 2018
Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone diseaseJoséphine Muller, Arnold Bolomsky, Sophie Dubois, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG ConditioningMuriel Hannon, Yves Beguin, Grégory Ehx, et al.
Clinical Biochemistry|December 27, 2016
The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian studyFlorence Van Obbergh, Laurent Knoops, Timothy Devos, et al.
Bulletin Du Cancer|September 6, 2025
[Acute graft-versus-host disease therapy: Which third line treatment after steroids and ruxolitinib? (SFGM-TC)]Tereza Coman, Fabio Andreozzi, Jaques-Olivier Bay, et al.
Transplantation and Cellular Therapy|August 24, 2022
Unrelated Cord Blood Transplantation in Children, Adolescents, and Young Adults with Acute Leukemia or Myelodysplastic Syndrome: A Retrospective Comparative Study from the French Society for Bone Marrow Transplantation and Cellular Therapy Between Real-World Data and Previously Reported Results of a Randomized Clinical TrialAnne-Charlotte Teyssier, Gérard Michel, Charlotte Jubert, et al.
Frontiers in Immunology|February 23, 2023
Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: A multicenter prospective analysisSophie Servais, Frédéric Baron, Chantal Lechanteur, et al.
The Oncologist|February 28, 2016
The Changing Landscape of Smoldering Multiple Myeloma: A European PerspectiveJo Caers, Carlos Fernández de Larrea, Xavier Leleu, et al.
Frontiers in Immunology|October 19, 2018
Growth Hormone (GH) Deficient Mice With GHRH Gene Ablation Are Severely Deficient in Vaccine and Immune Responses Against <i>Streptococcus pneumoniae</i>Khalil Farhat, Gwennaëlle Bodart, Chantal Charlet-Renard, et al.
Haematologica|March 20, 2016
Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen for elderly patients (60 years and older) with hematologic malignancies using unrelated donors: a retrospective study from the French society for stem cell transplantation (SFGM-TC)Jean El Cheikh, Patrick Sfumato, Mohamad Sobh, et al.
Pageof 25